Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Overview of attention for article published in Journal of Clinical Oncology, August 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 3 news outlets
policy: 3 policy sources
twitter: 65 X users

patent: 3 patents
facebook: 4 Facebook pages
reddit: 1 Redditor

Citations

dimensions_citation: 469 Dimensions

Readers on

mendeley: 371 Mendeley

Summary News Policy documents X Patents Facebook Reddit Dimensions citations

So far, Altmetric has seen 4 news stories from 3 outlets.

ASCO Guideline on Stage IV NSCLC Therapy Updated

The ASCO Post, 16 Aug 2017

By The ASCO Post Posted: 8/16/2017 9:47:56 AM Last Updated: 8/16/2017 10:14:36 AM Tweet this page Advertisement An update of…

Panel Backs PD-L1 Drugs for First Line in NSCLC

MedPage Today, 15 Aug 2017

MedpageToday by Charles Bankhead Senior Associate Editor, MedPage Today August 15, 2017 Patients with PD-L1 positive advanced…

FDA Approves New ROS1 Indication for Xalkori With Post-Marketing CDx Commitment

Genomeweb, 17 Mar 2016

NEW YORK (GenomeWeb) – In approving Pfizer's non-small cell lung cancer drug Xalkori (crizotinib) last week in metastatic…

ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC

The ASCO Post, 24 Nov 2015

As reported in the Journal of Clinical Oncology by Gregory A. Masters, MD, and colleagues, ASCO has issued a clinical practice…